Authors analyzed mutations in IDH1, IDH2, TP53, TERT, ATRX, H3F3A, and HIST1H3B across two diffuse glioma cohorts from The Cancer Genome Atlas (TCGA), totaling 648 tumor samples. This evidence concerns the gene IDH1 and neoplasm.